- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04538742
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer (DB-07)
A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is modular in design allowing assessment of safety, tolerability and anti-tumour activity of T-DXd in combination with other anti-cancer agents. Combination-treatment modules will have 2 parts: a dose-finding phase (Part 1), and a dose expansion phase (Part 2); the recommended Phase 2 dose (RP2D) determined in Part 1 will be used for the dose-expansion in Part 2.
The target population of interest in this study is patients with HER2-positive (as per ASCO/CAP 2018 guidelines) advanced/MBC inclusive of patients with active and stable brain metastases. Part 1 of each module will enroll patients with locally assessed HER2-positive advanced/MBC in second-line or later patients. Part 2 of each module will enroll patients with locally assessed HER2-positive breast cancer who have not received prior treatment for advanced/metastatic disease.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Melbourne, Australia, 3000
- Research Site
-
-
-
-
-
Barretos, Brazil, 14784-400
- Research Site
-
Belo Horizonte, Brazil, 30150-274
- Research Site
-
Natal, Brazil, 59075-740
- Research Site
-
Porto Alegre, Brazil, 90610-000
- Research Site
-
Porto Alegre, Brazil, 91350-200
- Research Site
-
Rio de Janeiro, Brazil, 20560-120
- Research Site
-
Sao Paulo, Brazil, 04029-000
- Research Site
-
Sao Paulo, Brazil, 01317-001
- Research Site
-
Sorocaba, Brazil, 18030-005
- Research Site
-
-
-
-
-
Quebec, Canada, G1S 4L8
- Research Site
-
Toronto, Canada, M5G 2M9
- Research Site
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 0A9
- Research Site
-
-
-
-
-
Villejuif Cedex, France, 94805
- Research Site
-
-
-
-
-
München, Germany, 81675
- Research Site
-
Würzburg, Germany, 97080
- Research Site
-
-
-
-
-
Delhi, India, 110085
- Research Site
-
Gurgaon, India, 122001
- Research Site
-
Madurai, India, 625107
- Research Site
-
Mumbai, India, 400012
- Research Site
-
-
-
-
-
Bologna, Italy, 40138
- Research Site
-
Milan, Italy, 20141
- Research Site
-
Napoli, Italy, 80131
- Research Site
-
Rome, Italy, 168
- Research Site
-
-
-
-
-
Busan-si, Korea, Republic of, 602-739
- Research Site
-
Seoul, Korea, Republic of, 05505
- Research Site
-
Seoul, Korea, Republic of, 03080
- Research Site
-
Seoul, Korea, Republic of, 02841
- Research Site
-
Seoul, Korea, Republic of, 06351
- Research Site
-
-
-
-
-
Bydgoszcz, Poland, 85-796
- Research Site
-
Koszalin, Poland, 75-581
- Research Site
-
Lublin, Poland, 20-090
- Research Site
-
Łódź, Poland, 90-242
- Research Site
-
-
-
-
-
Moscow, Russian Federation, 115478
- Research Site
-
Moscow, Russian Federation, 111123
- Research Site
-
Moscow, Russian Federation, 117997
- Research Site
-
Moscow, Russian Federation, 121205
- Research Site
-
Moscow, Russian Federation, 143423
- Research Site
-
Moscow, Russian Federation, 105229
- Research Site
-
Moscow, Russian Federation, 109240
- Research Site
-
Saint Petersburg, Russian Federation, 195271
- Research Site
-
Sankt-Peterburg, Russian Federation, 197758
- Research Site
-
Sankt-Peterburg, Russian Federation, 196603
- Research Site
-
-
-
-
-
Barcelona, Spain, 08003
- Research Site
-
L'Hospitalet de Llobregat, Spain, 08908
- Research Site
-
Madrid, Spain, 28050
- Research Site
-
Madrid, Spain, 28007
- Research Site
-
Sevilla, Spain, 41013
- Research Site
-
-
-
-
-
Hualien, Taiwan, 970
- Research Site
-
Tainan, Taiwan, 704
- Research Site
-
Taipei, Taiwan, 235
- Research Site
-
Taipei, Taiwan, 10449
- Research Site
-
Taipei, Taiwan, 11217
- Research Site
-
Taipei, Taiwan, 10048
- Research Site
-
Taipei City, Taiwan, 114
- Research Site
-
Taoyuan City, Taiwan, 333
- Research Site
-
-
-
-
-
Ankara, Turkey, 6100
- Research Site
-
Edirne, Turkey, 22030
- Research Site
-
Istanbul, Turkey, 34722
- Research Site
-
Istanbul, Turkey, 34662
- Research Site
-
Izmir, Turkey, 35100
- Research Site
-
-
-
-
-
Buckhurst Hill, United Kingdom, IG9 5HX
- Research Site
-
-
-
-
Florida
-
Fort Myers, Florida, United States, 33901
- Research Site
-
Saint Petersburg, Florida, United States, 33705
- Research Site
-
-
New York
-
Commack, New York, United States, 11725
- Research Site
-
Harrison, New York, United States, 10604
- Research Site
-
New York, New York, United States, 10016
- Research Site
-
New York, New York, United States, 10065
- Research Site
-
-
Ohio
-
Columbus, Ohio, United States, 43219
- Research Site
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Research Site
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- Research Site
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Patients must be at least 18 years of age
Pathologically documented breast cancer that:
- Is advanced/unresectable (patients that can be treated with curative intent are not eligible) or metastatic
- HER2-positive (IHC 3+ or IHC 2+/ISH+) based on local assessment. The local HER2 result must be from a tumour sample obtained in the metastatic setting.
- Is documented as hormone receptor-positive (estrogen or progesterone receptor) or negative in the metastatic setting
- Patient must have adequate tumor sample from the metastatic setting for biomarker assessment
- ECOG Performance Status of 0 or 1
Part 1
- Disease progression on or after the last systemic therapy prior to starting study treatment
- At least 1 prior treatment line in metastatic setting required.
Part 2 (Modules 0 - 5)
a) No prior lines of therapy for advanced/MBC allowed
- Part 2 (Module 6 and 7) a) Zero or one prior lines of therapy for advanced/MBC allowed
CNS Inclusion
- Modules 0 - 5 Patients must have no brain metastases or stable brain metastases.
- Module 6 and 7 Patients must have untreated brain metastases not needing local therapy or previously treated brain metastases that have progressed since prior local therapy
Key Exclusion Criteria:
- Uncontrolled or significant cardiovascular disease
- Active or prior documented (non-infectious) ILD/pneumonitis that required steroids, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
- Lung-specific intercurrent clinically significant illnesses
- Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals
- Spinal cord compression or a history of leptomeningeal carcinomatosis
- Prior treatment with immune checkpoint inhibitors
- Prior treatment with an ADC containing a topoisomerase I inhibitor
- Prior treatment with tucatinib
CNS Exclusion
- Modules 0 - 5: Has untreated brain metastasis
- Module 6 and 7: Ongoing use of systemic corticosteroids for control of symptoms of brain metastases at a total daily dose of > 2 mg dexamethasone or any brain lesion thought to require immediate local therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Module 1- T-DXd and Durvalumab
T-DXd and Durvalumab
|
T-DXd: administered as an IV infusion
Other Names:
Durvalumab: administered as an IV infusion
Other Names:
|
Experimental: Module 2- T-DXd and Pertuzumab
T-DXd and Pertuzumab
|
T-DXd: administered as an IV infusion
Other Names:
Pertuzumab: administered as an IV infusion
|
Experimental: Module 0- T-DXd
T-DXd
|
T-DXd: administered as an IV infusion
Other Names:
|
Experimental: Module 7 - T-DXd
T-DXd monotherapy in patients with active brain metastases (Part 2 Only)
|
T-DXd: administered as an IV infusion
Other Names:
|
Experimental: Module 3- T-DXd and Paclitaxel
T-DXd and Paclitaxel (Arm not initiated in Part 2)
|
T-DXd: administered as an IV infusion
Other Names:
Paclitaxel: administered as an IV infusion
|
Experimental: Module 4- T-DXd and Durvalumab and Paclitaxel
T-DXd and Durvalumab and Paclitaxel (Arm not initiated in Part 1 and Part 2)
|
T-DXd: administered as an IV infusion
Other Names:
Durvalumab: administered as an IV infusion
Other Names:
Paclitaxel: administered as an IV infusion
|
Experimental: Module 5 - T-DXd and Tucatanib
T-DXd and tucatinib (Arm not initiated in Part 2)
|
T-DXd: administered as an IV infusion
Other Names:
Tucatinib administered orally (tablet) twice daily
Other Names:
|
Experimental: Module 6 - T-DXd and Tucatinib
T-DXd and tucatinib in patients with active brain metastases (Part 2 Only) (Arm not initiated)
|
T-DXd: administered as an IV infusion
Other Names:
Tucatinib administered orally (tablet) twice daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of adverse events (AEs)- Part 1
Time Frame: Up to follow-up period, approximately 53 months
|
Occurrence of AEs in Part 1 graded according to NCI CTCAE v5.0
|
Up to follow-up period, approximately 53 months
|
Occurrence of serious adverse events (SAEs)- Part 1
Time Frame: Up to follow-up period, approximately 53 months
|
Occurrence of SAEs in Part 1 graded according to NCI CTCAE v5.0
|
Up to follow-up period, approximately 53 months
|
Occurrence of adverse events (AEs)- Part 2
Time Frame: Up to follow-up period, approximately 53 months
|
Occurrence of AEs in Part 2 graded according to NCI CTCAE v5.0
|
Up to follow-up period, approximately 53 months
|
Occurrence of serious adverse events (SAEs)- Part 2
Time Frame: Up to follow-up period, approximately 53 months
|
Occurrence of SAEs in Part 2 graded according to NCI CTCAE v5.0
|
Up to follow-up period, approximately 53 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)- Part 1 and Part 2
Time Frame: Until progression, assessed up to approximately 53 months
|
ORR is defined as the proportion of patients who have a CR or PR, as determined by the Investigator at local site per RECIST 1.1.
|
Until progression, assessed up to approximately 53 months
|
Progression Free Survival (PFS)- Part 1 and Part 2
Time Frame: Until progression, assessed up to approximately 53 months
|
PFS is defined as time from the date of randomization until the date of progression as assessed by the Investigator at local site per RECIST 1.1, or death due to any cause.
|
Until progression, assessed up to approximately 53 months
|
Progression Free Survival 2 (PFS2)- Part 2
Time Frame: Assessed up to approximately 53 months
|
PFS2 is defined as time from the date of randomisation until the date of progression on next line treatment (the earliest of the progression event subsequent to first subsequent anticancer therapy) or death; second progression will be defined according to local standard clinical practice.
|
Assessed up to approximately 53 months
|
Duration of Response (DoR)- Part 2
Time Frame: Until progression, assessed up to approximately 53 months
|
DoR is defined as time from the date of first documented response until the date of documented progression or death in the absence of disease progression.
|
Until progression, assessed up to approximately 53 months
|
Overall Survival (OS)- Part 2
Time Frame: Until death, assessed up to approximately 53 months
|
OS is defined as time from the date of randomisation until the date of death due to any cause.
|
Until death, assessed up to approximately 53 months
|
Serum Concentration of Trastuzumab Deruxtecan (T-DXd)
Time Frame: While on study drug up to study completion, approximately 53 months
|
Determination of trastuzumab deruxtecan concentration in serum at different time points after trastuzumab deruxtecan administration
|
While on study drug up to study completion, approximately 53 months
|
Serum Concentration of Durvalumab
Time Frame: While on study drug up to study completion, approximately 53 months
|
Determination of durvalumab concentration in serum at different time points after administration
|
While on study drug up to study completion, approximately 53 months
|
Serum Concentration of Pertuzumab
Time Frame: While on study drug up to study completion, approximately 53 months
|
Determination of pertuzumab concentration in serum at different time points after administration
|
While on study drug up to study completion, approximately 53 months
|
Plasma Concentration of Paclitaxel
Time Frame: While on study drug up to study completion, approximately 53 months
|
Determination of paclitaxel concentration in plasma at different time points after administration
|
While on study drug up to study completion, approximately 53 months
|
Plasma Concentration of Tucatinib
Time Frame: While on study drug up to study completion, approximately 53 months
|
Determination of tucatinib concentration in plasma at different time points after administration
|
While on study drug up to study completion, approximately 53 months
|
Immunogenicity of trastuzumab deruxtecan
Time Frame: Up to follow-up period, approximately 53 months
|
Percentage of patients who develop ADA for trastuzumab deruxtecan
|
Up to follow-up period, approximately 53 months
|
Immunogenicity of Durvalumab
Time Frame: Up to follow-up period, approximately 53 months
|
Percentage of patients who develop ADA for durvalumab
|
Up to follow-up period, approximately 53 months
|
Immunogenicity of Pertuzumab
Time Frame: Up to follow-up period, approximately 53 months
|
Percentage of patients who develop ADA for pertuzumab
|
Up to follow-up period, approximately 53 months
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Protein Kinase Inhibitors
- Immunoconjugates
- Paclitaxel
- Trastuzumab
- Durvalumab
- Pertuzumab
- Tucatinib
- Trastuzumab deruxtecan
Other Study ID Numbers
- D967JC00001
- 2019-004531-22 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
Clinical Trials on Trastuzumab deruxtecan
-
AstraZenecaDaiichi SankyoCompletedBreast CancerDenmark, Finland, Italy, Norway, Spain, Sweden, Poland, United States, Canada, Germany, Japan, Netherlands, Portugal, Switzerland, Australia, United Kingdom, Belgium, Ireland
-
Fudan UniversityNot yet recruitingTriple-Negative Breast CancerChina
-
AstraZenecaDaiichi Sankyo Co., Ltd.Active, not recruitingGastric or Gastroesophageal Junction (GEJ) AdenocarcinomaChina
-
Daiichi Sankyo, Inc.AstraZenecaRecruiting
-
MedSIRDaiichi Sankyo, Inc.Not yet recruitingBreast Cancer | Metastatic Breast Cancer
-
Cancer Trials IrelandRecruitingHER2-positive Breast CancerIreland
-
Fudan UniversityActive, not recruiting
-
Cancer Institute and Hospital, Chinese Academy...Not yet recruiting
-
Medical University of ViennaDaiichi Sankyo, Inc.CompletedBreast Cancer Stage IVAustria
-
National Cancer Institute (NCI)RecruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditionsUnited States